Level C· Early human research exploring benefitsProspective StudyEurope PMCOpen access

Surgical Management of Perianal Crohn's Disease: Current Evidence and Future Directions

Busbait S.

Prospective Study on Chronic Wound, Autoimmune Research, published in Acta Inform Med (2024) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
Acta Inform Med (2024)
Reported sample size
—
Source database
Europe PMC
PMID
40061009
PMCID
PMC11889424
DOI
10.5455/aim.2024.32.215-220

Abstract (original English)

Background Perianal manifestations of Crohn's disease (CD) are common, with fistulas being the most prevalent and challenging to manage. Objective The aim of this articles was to describe and explain how Perianal fistulizing Crohn's disease significantly impacts patients' quality of life and poses a therapeutic challenge for clinicians. Methods The author used published papers deposited in index databases PubMed Central, Scopus, HINARY etc. rergarding Surgical Management of Perianal Crohn's Disease: Current Management requires a multidisciplinary and multimodal approach, integrating both medical and surgical interventions tailored to disease severity and fistula complexity. Results and discussion Despite advancements in therapy, the majority of patients require multiple interventions due to high rates of primary non-healing, surgical morbidity, and recurrence..Medical treatment primarily includes biologics, particularly anti-TNF agents such as infliximab and adalimumab, which have demonstrated efficacy in fistula closure and symptom control. Surgical approaches remain critical with various degrees of success. Conslusion Despite the availability of multiple therapeutic options, Perianal fistulizing Crohn's disease remains a complex condition with ongoing challenges in achieving sustained remission. Future research should focus on novel treatment strategies and optimizing individ

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research